|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 11 (December 1), 1998:
pp. 4167-4177
Role of Tissue Factor in Adhesion of Mononuclear Phagocytes to and
Trafficking Through Endothelium In Vitro
By
Gwendalyn J. Randolph,
Thomas Luther,
Sybille Albrecht,
Viktor Magdolen, and
William A. Muller
From the Department of Pathology, Cornell University Medical College,
New York, NY; the Institute of Pathology, Technical University of
Dresden, Dresden; and the Department of Gynecology, Technical
University of Munich, Munich, Germany.
 |
ABSTRACT |
An in vitro model consisting of endothelium grown on
collagen was used to investigate how mononuclear phagocytes traverse endothelium in the basal-to-apical direction (reverse transmigration), a process that mimics their migration across vascular and/or
lymphatic endothelium during atherosclerosis and resolution of
inflammation, respectively. Monoclonal antibody (MoAb) VIC7 against
tissue factor (TF) inhibited reverse transmigration by 77%.
Recombinant tissue factor fragments containing at least six amino acids
C-terminal to residue 202 also strongly inhibited reverse
transmigration. TF was absent on resting monocytes but was induced on
these cells after initial apical-to-basal transendothelial migration.
Two additional observations suggest that TF is involved in adhesion between mononuclear phagocytes and endothelium: (1) when monocytes were
incubated with lipopolysaccharide (LPS) to stimulate expression of TF
before they were added to endothelium, VIC7 or soluble TF modestly
inhibited their adhesion to the apical endothelial surface, each by
about 35%; and (2) endothelial cells specifically bound to surfaces
coated with TF fragments containing amino acids 202-219. This binding
was blocked by anti-TF MoAb, suggesting that endothelial cells bear a
receptor for TF. These data suggest that mononuclear phagocytes use TF, perhaps as an adhesive protein, to exit sites of
inflammation.
© 1998 by The American Society of Hematology.
| |
INTRODUCTION |
TISSUE FACTOR (TF), a 47-kD transmembrane
protein, initiates the extrinsic pathway of coagulation via formation
of an enzymatic complex with factor VII/factor VIIa (factor VII[a]). Its constitutive expression by mesenchymal cells residing in the adventitial lining of blood vessels normally precludes its interaction with factor VII in plasma but allows rapid activation of coagulation when blood vessel barriers are broken.1 TF may also possess biological functions that are independent of the clotting cascade; TF
is expressed in early stages of embryogenesis before factor VII(a) is
present.2 In contrast to factor VII,3 TF is
essential for development, as shown by inactivation of the murine TF
gene.4-6 TF expressed by tumor cells promotes
vascularization of the tumor, even in the presence of potent inhibitors
of coagulation.7 In addition, tumor cells bearing TF
display an enhanced capacity to metastasize. TF-dependent metastasis
requires VII(a) proteolytic activity8 but may also depend
on a role for TF that is independent of its coagulative functions.
Mutation of specific residues in the cytoplasmic tail of TF prevent
metastasis, even though modification of these residues does not impair
the binding and activation of factor VII(a).8,9
Proinflammatory stimuli induce expression of TF on mononuclear
phagocytes (MP), dendritic cells, and endothelium.1
Induction of TF on circulating monocytes after activation with
lipopolysaccharide (LPS) or tumor necrosis factor- (TNF-) is a
major complication in septic shock, leading to disseminated
intravascular coagulation.10 The central role of TF in
septic shock is evident from the findings that neutralizing monoclonal
antibodies (MoAbs) to TF block LPS-mediated intravascular coagulation
in chimpanzees11 and lethality in baboons after
administration of LPS.12 In another setting, expression of
TF on macrophages and endothelial cells in atherosclerotic plaques13-15 may also lead to thrombosis. Our interest in
mediators of inflammatory reactions, particularly those that promote
resolution of such reactions, led to the present study that points to a
novel role for TF in inflammation.
As acute inflammation resolves, MP are cleared from inflammatory foci
by migrating to draining lymph nodes,16,17 a process that
entails crossing lymphatic endothelium in the basal-to-apical direction
(reverse transmigration). Reverse transmigration has also been
documented in atherosclerosis,14,18-20 a form of chronic inflammation. Indeed, reverse transmigration of MP-derived foam cells
across arterial endothelium may represent a mechanism by which
atherosclerotic lesions can regress.14,18 A previous study
using an in vitro model of a blood vessel wall showed that a majority
of MP that initially migrate across endothelium to enter underlying
connective tissue later exited the cultures by migrating back across
the endothelium in the reverse direction.21 Because little
is known about the molecular events that promote reverse transmigration
in vitro or in vivo, we initially set out to identify important
mediators. Our findings indicate that TF has an important role in
reverse transmigration of MP. Although the exact mechanism for this is
not known, we show that under conditions in which monocytes are
stimulated to express TF, it contributes to the adhesion of these
activated monocytes to endothelium. Moreover, we find that endothelial
cells express binding sites for TF.
| |
MATERIALS AND METHODS |
Antibodies and recombinant proteins.
A panel of anti-TF MoAbs including VD8, VIC7, VIC12, IIID8, VD10, VIC6,
and IVC622; anti-factor VII(a) MoAbs IVE4 and
IIH223; hec7 MoAb against platelet/endothelial cell
adhesion molecule-124; and hec1 MoAb against cadherin
525 were produced and characterized previously . Anti-CD14
MoAb 3C10, anti-vascular cell adhesion molecule 1 MoAb 4B9, and
anti-CD3 MoAb Leu4 were gifts from Drs Samuel Wright (Merck, Rahway,
NJ), John Harlan (University of Washington, Seattle), and James Young
(Rockefeller University), respectively. Fluorescein isothiocyanate
(FITC)-conjugated anti-CD45 MoAb was purchased from Becton Dickinson
(San Jose, CA). All other MoAbs used were obtained from the VIth
International Workshop on Human Leukocyte Differentiation Antigens.
Goat anti-TF polyclonal antibody was purchased from American
Diagnostica (Greenwich, CT). Purified, nonlipidated fragments of
soluble recombinant human TF representing various regions of the
extracellular domain, expressed in Escherichia coli, were
prepared as described.26 Additional soluble recombinant TF
was the generous gift of Drs Yale Nemerson and Arabinda Guha (Mt Sinai
Medical Center, New York, NY). Reagents used in transmigration
experiments, including MoAbs, were tested for LPS using the limulus
amebocyte lysate assay purchased from BioWhittaker, Inc (Walkersville,
MD).
Transendothelial migration assays.
In vitro cultures to mimic a blood vessel wall were prepared using a
minor variation of a well-characterized method.27 In brief,
HUVEC were grown on type I collagen gels in microtiter wells and were
maintained in Medium 199 (M199) containing 20% fetal bovine serum
(FBS) or 20% heat-inactivated human serum. FBS without detectable
levels of LPS was obtained from HyClone Laboratories (Logan, UT). In
some experiments, collagen gels were polymerized in the presence of 2.5 × 10-4% FITC-conjugated, 0.5-µm diameter
polystyrene microspheres from Polysciences (Warrington, PA) before
adding HUVEC.
For transmigration experiments, freshly isolated peripheral blood
mononuclear cells (PBMC)27 or PBMC cultured for 4 hours in
10% FBS/M199 with or without addition of 2 ng/mL of LPS were resuspended in 0.1% HSA/M199 and added to HUVEC cultures that had been
confluent for at least 3 days. Monocytes, but not lymphocytes, transmigrate across unstimulated endothelial monolayers by 1 hour of
coincubation.27 In some experiments, HUVEC monolayers were pretreated with 10 ng/mL recombinant human TNF- (Genzyme; Cambridge, MA) for 4 hours before adding monocytes. For experiments involving TNF-activated endothelium, PBMC were further purified to yield 70%
monocytes by negative selection as follows: PBMC were incubated with 1 µg/mL Leu4 MoAb for 30 minutes on ice and then magnetic beads
conjugated to goat anti-mouse IgG, purchased from Dynal (Lake Success,
NY), were added at a ratio of 5 beads/cell and incubated with gentle
inversion at 4°C for 30 additional minutes. CD3+
T-lymphocytes and free magnetic beads were depleted using a strong magnet.
For reverse transendothelial migration assays, PBMC were incubated with
endothelium for 1 or 2 hours to allow accumulation of monocytes in the
subendothelial collagen. Then cultures were rinsed in M199 to remove
nonmigrated cells (ie, lymphocytes), 20% FBS/M199 with or without
addition of MoAbs or polymyxin B (Sigma Chemical Co, St Louis, MO) was
added, and incubation was continued. At 24-hour intervals until the end
of the experiment, cultures were rinsed in M199 to remove nonadherent
MP that may have accumulated in the apical compartment by reverse
transmigration, and medium was replenished. Experiments included six
replicates per parameter tested.
Experiments were analyzed by using one or both of the following
methods: (1) Cultures were fixed in glutaraldehyde, stained with eosin
and methylene blue, and the number of MP beneath the endothelium were
counted in five high-power fields during an en face microscopic
examination using Nomarski interference optics.25 To
confirm whether MP in the cultures were adherent to the apical surface
of the endothelial monolayer or present beneath the endothelium, some
cultures were embedded in JB-4 glycol methacrylate (Polysciences), transverse sections (2-µm) were prepared, and the disposition of MP
relative to the endothelium was determined. (2) An automated technique
was used to evaluate total cell number by quantitating total DNA/well
using the dye Yo-Pro-1 from Molecular Probes (Eugene, OR), which
fluoresces after binding DNA. MP adherent to the apical surface of the
endothelium were removed from wells before evaluation with Yo-Pro-1 by
washing the cultures twice in cold Hanks' balanced salt solution
(HBSS) containing 1 mmol/L EGTA and then twice more in plain HBSS.
Plates containing subendothelial MP and endothelium were frozen and
thawed, incubated for 1 hour at 37°C after addition of 100 µL
distilled water/well, and frozen and thawed once more before addition
of 100 µL of Yo-Pro-1 (4 µmol/L in Tris buffer [10 mmol/L]
containing NaCl [2 mol/L] and EDTA [1 mmol/L]). Fluoresence was
measured using a Cytofluor 2350 fluorescence measurement system from
PerSeptive Biosystems (Framingham, MA). The intensity of fluorescence
in wells containing only endothelium was subtracted from the intensity
of fluorescence in wells containing both MP and endothelium in the same
assay plate, allowing an assessment of the relative number of MP
beneath the endothelium. Percent reverse transmigration was calculated
as the percentage decrease in the number of MP beneath the endothelial
monolayer compared with the number that initially accumulated below the
endothelium at 2 hours of incubation.
Chemotaxis assay.
Solutions of FMLP (Sigma) or soluble recombinant TF, prepared in 0.1%
HSA/M199, were placed in the lower compartments of a 48-well chemotaxis
chamber from Neuroprobe, Inc (Cabin John, MD) in the presence or
absence of added MoAb. MP resuspended in 0.1% HSA/M199, with or
without addition of MoAb, were placed in the upper compartment of the
chambers, which was separated from the lower compartment by a cellulose
nitrate filter (Neuroprobe, Inc) permeated with 5.0-µm pores or an
8.0-µm filter coated with type I bovine collagen. The chambers were
incubated for 90 minutes at 37°C and then fixed and stained with
hematoxylin.28 Five 400× fields per filter were
evaluated microscopically to determine the number of MP that had
migrated to depths of 25 and 50 µm within the filter. At these
depths, significant numbers of MP (20 to 50 cells/field) were found in
positive controls, but few in negative controls. For coating filters
with collagen, individual filters were submerged in a solution of
monomeric type I bovine collagen (1.7 mg/mL) purchased from Celtrix
(Palo Alto, CA) and incubated at 37°C for 20 minutes to allow
polymerization. Excess polymerized collagen was removed from the
surface of the filter by rotating it gently in M199.
In other experiments, collagen gels in 96-well plates were equilibrated
with FMLP (10-7 mol/L), then rinsed for 10 minutes in M199
lacking FMLP. This technique allows for the development of a gradient
of FMLP that increases with increasing depth of collagen. Reverse
transmigrated MP were applied to these gels in the presence or absence
of anti-TF MoAb or control MoAb. Cultures were incubated for 2 hours,
then rinsed and (1) fixed or (2) processed for cell quantitation using Yo-Pro-1 as described above. In fixed samples, the depth of MP penetration into the gel was assessed.
Flow cytometry.
Before staining for flow cytometry, endothelial cells and MP residing
on/within collagen gels were separated from this matrix by solubilizing
the collagen using 1 mg/mL collagenase (Worthington, Freehold, NJ) at
37°C for 25 minutes. Cell suspensions were resuspended in 5% human
serum/M199. MoAbs against surface antigens were added to the
suspensions at 10 µg/mL and incubated on ice for 30 minutes. Cells
were washed twice in 0.1%HSA/HBSS, incubated in 1:100 dilution of
FITC-conjugated goat anti-mouse IgG (Dako; Carpinteria, OR) for 30 minutes at 4°C, and finally washed twice in 0.1%HSA/HBSS. Fluorescence intensity was measured using a Becton Dickinson FACScan, in which 10,000 events were collected per sample.
Clotting assay.
A one-stage clotting assay was conducted essentially as previously
described.22 Cell samples and human plasma (100 µL each) were mixed and warmed for 1 minute at 37°C, followed by addition of
25 mmol/L CaCl2 (100 µL). The number of seconds that
elapsed until the formation of a visible clot was measured. Using
bovine lung thromboplastin (ICN, Costa Mesa, CA) as a standard, a
linear curve was obtained across the tested concentration range of 0.1 to 1,000 mU procoagulant activity (PCA; log-log plot). For clotting assays conducted on cells cultured in collagen gels, intact collagen gels were removed from the microtiter wells and mixed with human plasma
before starting the clotting assay. Alternatively, cultures were frozen
and thawed. Then cells were lysed and solubilized by successive
addition of 15 mmol/L 1-O-n-octyl- -D-glucopyranoside purchased from
Boehringer Mannheim (Indianapolis, IN; 30 µL) and HEPES-buffered
saline solution (70 µL). Thus, treated cultures were removed from
microtiter wells for assessement of PCA. The latter procedure enhanced
the detection of PCA in cultures by approximately two-fold.
Cell adhesion assay.
Ninety-six well enzyme-linked immunosorbent assay (ELISA) plates from
Nunc (Wiesbaden, Germany) were coated overnight with 5 µg/mL TF
fragments or bovine serum albumin (BSA) in carbonate buffer (15 mmol/L
Na2CO3, 33 mmol/L NaHCO3, pH 9.5).
The plates were washed two times with phosphate-buffered saline (PBS;
pH 7.6), and thereafter blocked with 0.2% BSA in PBS for 30 minutes at
37°C. HUVEC (passage 3 to 5) were harvested and resuspended in
Endothelial Cell Basal Medium (PromoCell, Heidelberg, Germany) with
Supplement Pack (PromoCell; contains FBS, endothelial cell growth
supplement, human epidermal growth factor, human basic fibroblast
growth factor, HC-500, gentamicin, amphotericin B). For some samples,
this medium also included 50 µg/mL anti-TF MoAb or 50 µg/mL control
MoAb. Cells were seeded (20,000 cells/well) onto plates for 1, 2, or 5 hours, as indicated. Nonadherent cells were removed by two washes in
PBS. Adherent cells were quantified by measuring the enzymatic cleavage
of the tetrazolium salt XTT to formazan by mitochondrial
succinate-tetrazolium reductase (Boehringer Mannheim, Germany). The
color reaction was measured at 450 nm. A reference curve was
established by incubating different cell numbers on a separate plate
from the time when the cells were seeded to the plates.
Statistics.
The Mann-Whitney U test was used for statistical analysis, using SPSS
software.
| |
RESULTS |
In vitro model to study reverse transendothelial migration.
The in vitro model used herein, consisting of HUVEC grown on
reconstituted bovine type I collagen, has been well characterized with
respect to the initial diapedesis of monocytes to enter the underlying
collagen.25,27 The subsequent exit of MP from HUVEC cultures by basal-to-apical migration back across the endothelium (reverse transmigration) has been investigated previously using a
different model in which HUVEC are grown on amniotic
stroma.21 Likewise, in the present model, MP that enter the
subendothelial collagen later exit the cultures by retraversing the
endothelium with a t1/2 of 48 hours
(Fig 1A). The endothelial
monolayer remained intact throughout these experiments. A direct
comparison between two methods that were used to analyze reverse
transmigration experiments yielded similar results (Fig 1A).
View larger version (15K):
[in this window]
[in a new window]
| Fig 1.
Basal-to-apical transendothelial migration of
MP. (A) Unstimulated endothelial cells grown on collagen were incubated
with PBMC for 2 hours, then rinsed to remove nonadherent cells. Some
cultures were then processed for analysis; others were incubated
further for as long as 7 days. Two methods were used to analyze reverse
transmigration experiments: visual enumeration of MP beneath
endothelial monolayers using Nomarski interference optics (filled
squares) and assessment of MP content in cultures using the DNA-binding
dye Yo-Pro-1 (filled diamonds). Percent reverse transmigration is
defined as the percentage decrease in the number of MP beneath the
endothelium, relative to the number of subendothelial MP at 2 hours.
(B) Some cultures were prepared that contained FITC-conjugated beads
embedded in the collagen. Using flow cytometry, the uptake of these
beads by MP that migrated into the collagen was assessed at 24 hours,
after the cells were removed from the collagen with collagenase, and
compared to the extent of beads associated with MP that accumulated in
the apical compartment of parallel cultures between 24 and 48 hours of
incubation. Profiles represent histograms from a representative
experiment of MP collected from fluorescent bead-containing cultures
(shaded) or MP from cultures without beads (unshaded).
|
|
To show further that MP in this system were indeed retraversing the
endothelium in the basal-to-apical direction, we set up cultures in
which the collagen was polymerized in the presence of FITC-conjugated
microspheres. HUVEC were grown to confluence on this matrix, and
monocytes were added to the cultures and allowed to transmigrate. After
24 hours, some cultures containing subendothelial MP were resuspended
by digestion of the matrix with collagenase, and the MP were analyzed
by flow cytometry to determine the extent to which they had engulfed
the fluorescent beads. In parallel cultures that were not digested, MP
that accumulated in the apical compartment by reverse transmigration
were collected in the time interval between 24 and 48 hours and also
analyzed by flow cytometry. The MP collected from the apical
compartment at 48 hours had the same profile of fluorescence as those
found beneath the collagen at 24 hours (Fig 1B), indicating that the MP
had migrated beneath the endothelium, phagocytized the fluorescent
beads, and later exited the matrix by retraversing the endothelium.
Role of tissue factor in reverse transendothelial migration.
A variety of MoAbs were tested in reverse transendothelial migration
assays to search for molecules that mediate the interactions between MP
and endothelium during this process. Control experiments analyzed
whether MoAbs added to the apical side of endothelial monolayers could
penetrate these monolayers and bind to subendothelial antigens. Indeed,
FITC-conjugated MoAb against CD45, added to the apical aspect of
endothelial cultures just after monocytes had migrated beneath them,
successfully penetrated the endothelial barrier to bind to the CD45
antigen on the monocytes within 3 hours. This was determined by
digesting MoAb-treated cultures and examining the fluorescence
intensity of subendothelial monocytes by flow cytometry.
Even though MoAbs were thereby shown to have access to subendothelial
antigens, MoAbs against an extensive list of molecules that are known
to mediate binding between leukocytes and endothelium during
apical-to-basal transmigration revealed none that is essential for
reverse transmigration of MP for as long as 48 hours. For example,
neutralizing MoAbs to E-selectin,21 vascular cell adhesion molecule 1,21 and platelet/endothelial cell adhesion
molecule 129 have no effect on reverse transmigration.
Neutralizing MoAb to intercellular adhesion molecule 1 or the
2 subunit of integrins prevents reverse transmigration
of MP across interleukin-1 (IL-1)-stimulated HUVEC in the first 12 hours.21 However, when assays are conducted for 24 hours or
longer in the presence of these MoAbs, no inhibition of reverse
transmigration is observed using either cultures of HUVEC grown on
amniotic stroma (G.J. Randolph and M.B. Furie, unpublished
observations, June 1995) or in the culture system used
herein (Fig 2 and data not
shown).
View larger version (16K):
[in this window]
[in a new window]
| Fig 2.
Effect of MoAbs against TF on reverse
transendothelial migration of MP. PBMC were incubated with unstimulated
HUVEC grown on collagen gels for 2 hours to allow accumulation of
monocytes in the subendothelial collagen. Then cultures were washed to
remove nonadherent cells, and fresh medium with or without MoAbs (20 µg/mL) was added. After 24 hours, the cultures were rinsed, and MoAb
preparations were replenished. Cocultures of MP and HUVEC were
incubated for a total of 48 hours, and then analyzed for reverse
transmigration. Data are plotted relative to the percentage of reverse
transmigration observed in the absence of added MoAb. Anti-TF MoAbs
VIC7, HTF-K108, and HTF-K180 (all IgG1), and a variety of other IgG1
MoAbs, including TEA 1/31 against cadherin 5, F432G-3 against S-endo-4,
and OJ79 against MUC18, were tested in a single screening experiment
(A). The effect of anti-TF MoAb VIC7 was compared with that of
anti-CD11/CD18 MoAb IB4 in three experiments (B). Another group of
anti-TF MoAbs and an anti-factor VII MoAb were also evaluated in three
experiments (C). Statistical differences relative to controls with no
MoAb are denoted as (*), P < .02; (**), P < .005.
|
|
Screening of a large panel of MoAbs (>100) submitted to the VIth
International Workshop on Human Leukocyte Differentiation Antigens
revealed two MoAbs against TF that inhibited reverse transmigration
strongly for at least 48 hours (Fig 2A). In comparison, 55 other
isotype-matched MoAbs tested, including HTF-K180 against TF, had little
to no effect. A MoAb against p-glycoprotein (MRK16; IgG2a) also
specifically inhibited reverse transmigration.29 Anti-TF
MoAb VIC7 impeded reverse transmigration by 77 ± 22% in 12 experiments. A direct comparison of the effect of VIC7 against a
neutralizing MoAb to the integrin 2 subunit, IB4,
revealed no inhibition by the latter in the same three experiments in
which VIC7 prevented reverse transendothelial migration by 78 ± 15% (Fig 2B).
Examination of a larger panel of anti-TF MoAbs showed that VIC7 was by
far the most potent inhibitor of reverse transmigration, although a few
others inhibited modestly (Fig 2C). In contrast, anti-factor VII(a)
MoAbs IVE4 or IIH2 did not impede reverse transmigration (Fig 2C). None
of the MoAbs affected the total number of live cells in the cultures,
as assessed by adding the number of reverse-transmigrated MP collected
from above the endothelium to the number that remained beneath the
endothelium. All of the MoAbs used in the panel of anti-TF MoAbs
recognize 47-kD purified TF apoprotein in immunoblotting analysis and
are effective inhibitors of PCA.22 Epitope mapping studies
show that the epitopes for VIC7, VD10, IVC6, and VIC6 include
recognition of at least some of the amino acids between 181-214 or
175-202, whereas IIID8, VD8, and VIC12 recognize epitopes that are
contained in the first 25 amino acid residues of TF.26 Because VIC7 was the most potent inhibitor in the panel, its
specificity for TF was examned further by immunoblotting cell extracts
prepared from LPS-stimulated monocytes and HUVEC. VIC7 recognized a
single band of 47 kD in the LPS-stimulated cells, but not in the
unstimulated cell extracts, consistent with the induction of TF by LPS
(Fig 3).
View larger version (41K):
[in this window]
[in a new window]
| Fig 3.
Immunoblot of HUVEC and monocyte cell extracts with VIC7.
Lanes were loaded with cell extracts from unstimulated HUVEC (A);
LPS-stimulated HUVEC (B); freshly isolated, unstimulated monocytes (C);
and LPS-stimulated monocytes (D). Lanes contained approximately 40 mg
(HUVEC) or 20 mg (monocytes) total protein. A blank lane separates (B)
and (C).
|
|
Most MoAbs in this panel contained levels of LPS at approximately 0.2 to 1.0 endotoxin U/mL at a MoAb concentration of 20 µg/mL. When
tested in the present study, another control MoAb IH8 against
carcinoembryonic antigen, containing 1.0 endotoxin U/mL, did not
prevent reverse transmigration. Exogenous addition of LPS to cultures
at concentrations as high as 5 endotoxin (E) U/mL also did not block
(data not shown).
We also conducted reverse transmigration assays in the presence of
soluble, recombinant forms of human TF representing the complete amino
acid sequence of the extracellular region or fragments thereof,
expressed in E coli and used in delipidated form. When the
fragments were used at 5 to 20 µg/mL and assayed at 24-hour intervals, greater than 50% of the soluble recombinant TF fragment (residues 1-219) could be recovered in the supernatant of the cultures,
as quantitated by ELISA,22 indicating that the fragments were not degraded or consumed during incubation. Soluble TF impeded reverse transmigration by 69 ± 2% in eight independent experiments (Fig 4). Only fragments containing amino
acid residues carboxyl to residue 202 blocked reverse transmigration
effectively (Fig 4). This finding agrees well with the location of the
epitope for VIC7, which is between amino acids 181-214.26
View larger version (36K):
[in this window]
[in a new window]
| Fig 4.
Effect of soluble TF fragments on reverse
transendothelial migration of MP. A 48-hour reverse transmigration
assay was conducted as described in Fig 2. After 2 hours of incubation
during which monocytes accumulated beneath endothelial cell cultures,
medium containing anti-TF MoAb VIC7 (10 µg/mL), anti-VII MoAb IIH2
(10 µg/mL), soluble TF representing the full extracellular domain
(1-219), or partial fragments thereof was added to the cultures (5 µg/mL). Data are derived from three to eight independent experiments.
Statistical differences relative to controls with no MoAb are denoted
as (*), P < .05.
|
|
Expression of tissue factor in MP/HUVEC cocultures.
We next sought to examine the expression of TF in MP/HUVEC cocultures.
TF was not detected on freshly isolated monocytes, as examined by flow
cytometry (Fig 5A). At various time points after transmigration, cells were separated from the collagen by digestion with collagenase and then incubated with MoAbs for analysis. TF was induced on the surfaces of MP by 4 hours of coculture with endothelium (Fig 5A), but was not detected on MP after 1 hour of
coincubation (not shown). After 24 hours, TF remained present on MP
residing in subendothelial collagen (not shown), as well as on MP that
had egressed from the cultures by reverse transmigration (Fig 5A).
These 24-hour egressed MP did not require digestion for removal from
the cultures (Fig 5A). However, as a control, some 24-hour egressed MP
were treated with collagenase. This treatment did not change the
expression of TF (not shown). In contrast to its expression on MP, TF
was not observed on endothelial cell surfaces at any time (Fig 5A). In
most experiments, staining for TF was done using the MoAb VD10 against
TF. However, similar staining patterns were observed using the other
MoAbs to TF.
View larger version (31K):
[in this window]
[in a new window]
| Fig 5.
Expression of TF in MP/HUVEC cocultures. (A) Endothelial
cells cultured alone or endothelial cells coincubated with MP for 4 or
24 hours were treated thereafter with collagenase to prepare
single-cell suspensions. For other samples, reverse-transmigrated MP
were collected from the apical surface of intact cocultures (24-hour
egressed MP). The latter did not require collagenase for removal.
Aliquots of these suspensions were stained for flow cytometry using
MoAbs against vascular cell adhesion molecule 1 (4B9; negative control
for MP), cadherin 5 (hec 1; positive control for HUVEC), CD14 (3C10;
positive control for MP, negative control for HUVEC), and TF (VD10).
Dotted line profiles represent respective negative controls, solid
lines indicate positive controls, and filled profiles correspond to
cells stained for TF. MP and HUVEC were separated for analysis by
gating on their distinct forward-scatter and side-scatter profiles. (B)
The presence of TF in the cultures was also assessed by measuring PCA.
Plots represent the mean ± SD of PCA in three to six individual
96-well cultures. Data are representative of four experiments.
After incubation of monocytes with plain collagen gels or
endothelial monolayers grown on collagen for 1 hour in the absence of
added MoAb, cultures were washed to remove nonadherent lymphocytes.
Then 20% FBS/M199 was added, with inclusion of LPS (1 ng/mL), VIC7 (20 µg/mL), or VD10 (20 µg/mL) in some samples. Individual cultures
contained approximately 50,000 HUVEC on a 50-µL collagen gel and,
when present, about 50,000 MP. Accordingly, PCA shown for unstimulated
PBMC represents the activity observed in 50,000 peripheral blood
monocytes. At 24 hours, PCA derived from cells remaining in the
collagen gel was assessed separately from PCA in reverse-transmigrated
MP collected from the same cultures. PCA from reverse-transmigrated MP
is indicated by the stippled portion of the bar. For some samples, the
SD was too low to be visible in the constructed graphs. PCA detected in
HUVEC cultured alone was statistically increased over PCA in mock
cultures of collagen gels lacking cells (collagen was coated with
fibronectin and incubated in 20% FBS/M199 in similar fashion as the
other cultures), P < .005. PCA detected in 4-hour and 24-hour
cocultures of MP and HUVEC in the absence of added MoAb was
significantly greater than the activity in either HUVEC alone or
unstimulated PBMC, P < .005.
|
|
The presence of TF activity in cultures of MP and HUVEC was also
evaluated using a one-stage clotting assay (Fig 5B). PCA was not
detected in freshly isolated PBMC. In contrast, a low, but
statistically significant, level of PCA was measured in endothelial cell cultures (0.7 ± 0.2 mU in HUVEC cultured on collagen, compared with <0.1 mU in collagen gels without cells). PCA was increased by an
order of magnitude when the HUVEC monolayers were cocultured with MP.
An increase in PCA of similar magnitude was also observed when
monocytes were incubated with collagen gels (containing no detectable
LPS) in the absence of endothelium (Fig 5B; 4-hour MP on collagen).
This upregulation of PCA was sustained for at least 24 hours. At 24 hours, nearly half of the total PCA was recovered in the population of
reverse-transmigrated MP (Fig 5B, stippled portion of bar in 24-hour
cocultures). This population was comprised of 15,000 to 17,000 MP of
the approximately 50,000 total MP that initially migrated into the
collagen in each culture. In cultures that received MoAbs just after
monocytes transmigrated into the subendothelial matrix (1 hour), PCA
subsequently detected at 24 hours was inhibited by greater than 90% by
all anti-TF MoAbs (Fig 5B, VIC7 and VD10 are shown) and by 50% using
anti-VII(a) MoAbs. These data show that all anti-TF MoAbs had
equivalent access to and retention in MP/HUVEC cocultures. Because
anti-VII(a) MoAb did not completely inhibit PCA, we cannot eliminate a
role for VII(a)-mediated activity in reverse transmigration. However,
among the anti-TF MoAbs, there was no correlation between inhibition of
PCA and their effect on reverse transmigration. Addition of LPS to the
cocultures at 1 hour increased PCA by nearly 300-fold (Fig 5B). More
than 99% of this activity was inhibited by preincubating LPS-treated
cultures with VIC7 or VD10 before conducting the clotting assay (not
shown).
Role of tissue factor in interactions between mononuclear phagocytes
and endothelium.
TF, including nonlipidated recombinant soluble TF, possesses
chemotactic activity for smooth muscle cells.30 TF on MP
might also be required for general motility or adhesion. Therefore, chemotaxis assays measuring migration into collagen gels or migration across uncoated or collagen-coated cellulose nitrate filters were conducted. Freshly isolated monocytes or reverse-transmigrated MP
failed to migrate chemotactically toward concentrations of soluble TF
ranging from 1 pmol/L to 1.000 nmol/L, including 0.5 nmol/L
(Fig 6), which is optimally chemotactic for
smooth muscle cells,30 and 800 nmol/L (not shown), which
was maximally effective at blocking reverse transmigration. Moreover,
migration toward FMLP in nitrocellulose filters was unaffected by
anti-TF MoAb VIC7 (Fig 6). FMLP-stimulated penetration of MP into
collagen gels, prepared as for transmigration assays but without
endothelium, also was not affected by MoAb VIC7 or soluble recombinant
TF (data not shown). These data indicate that TF is neither chemotactic for MP nor essential for their migration on or through collagen.
View larger version (20K):
[in this window]
[in a new window]
| Fig 6.
Chemotaxis assay using soluble TF and anti-TF MoAb. Lower
wells of blind-well chambers were filled with control medium (No
Attractant) or medium containing 10 nmol/L FMLP, 10 nmol/L FMLP + 10 µg/mL anti-TF MoAb VIC7, or 0.5 nmol/L soluble TF.
Reverse-transmigrated MP collected from the apical aspect of 24-hour
cocultures with endothelium were resuspended in control medium with or
without added VIC7 (VIC7 was included in the apical compartment when it
was also used in the basal compartment) and added to the upper chamber
of chemotaxis wells. Stippled bars depict results obtained using
uncoated 5.0-µm cellulose nitrate filters; solid bars show results
using 8.0-µm collagen-coated filters. Data are representative of six
experiments.
|
|
Other experiments suggest that TF has a role in adhesion. The effect of
MoAb VIC7 on the initial interactions of monocytes with the apical
surface of the endothelium was evaluated using resting monocytes, which
do not express TF, and monocytes induced to express TF by stimulation
with LPS. VIC7 inhibited the adhesion of LPS-stimulated, but not
resting, monocytes to unstimulated or TNF-activated HUVEC by 35 ± 7% in four experiments. LPS-stimulated monocytes that were not
prevented from adhering in the presence of MoAb VIC7 migrated across
the endothelium, as observed by microscopic examination. These data
suggest that TF is involved in adhesion but does not affect subsequent
steps in apical-to-basal transendothelial migration. Recombinant
soluble TF inhibited this adhesion similarly, by 36 ± 9% in three
experiments (Fig 7).
View larger version (23K):
[in this window]
[in a new window]
| Fig 7.
Effect of anti-TF MoAb on adhesion of unstimulated and
LPS-stimulated monocytes to endothelium. Unstimulated monocytes or
LPS-stimulated monocytes were incubated with resting (black bars) or
TNF-activated (stippled bars) HUVEC grown on collagen for 1 hour in
medium without MoAb, or medium containing anti-TF MoAb VIC7,
anti-factor VII MoAb IVE4 (tested using unstimulated HUVEC only) at 10 µg/mL, or soluble recombinant TF (tested using unstimulated HUVEC
only; 20 µg/mL). The extent of binding was compared with the number
of monocytes that bound in the absence of added MoAb. The reduced
binding of LPS-stimulated monocytes observed in the presence of VIC7 or
recombinant TF is statistically different from the controls without
MoAb, P < .02 (*).
|
|
The former experiments are consistent with a model in which
MP-expressing TF use it to bind to a ligand on the endothelium. Therefore, experiments were conducted to explore whether such a ligand
might exist. Soluble TF fragments were immobilized in microtiter wells.
ELISA plates were used for these studies, instead of traditional tissue
culture-treated plates, because these plates support optimal protein
binding but little background adhesion of HUVEC. Unstimulated HUVEC
were added to wells coated with TF or control proteins in the presence
or absence of anti-TF MoAb for 2 hours. After 2 hours of incubation,
endothelial cell adhesion to TF fragments containing amino acid
residues 202-219 was greater than their binding to control surfaces or
to TF fragments lacking these residues
(Fig 8A). Spreading of HUVEC
during the first 2 hours was observed on surfaces coated with TF
fragments 97-219 (Fig 8B) or 1-219 (not shown), but to a much lesser
extent on surfaces coated with BSA (not shown) or the TF fragment
spanning amino acids 1-122 (Fig 8C). Together, these data identify a
region of TF between amino acid residues 202-219 that supports
accelerated adhesion and spreading of endothelial cells. Endothelial
cell binding to control surfaces was significantly lower than binding to fragments containing this region of TF, until after more than 5 hours of incubation when cells adhered well to all surfaces. Together,
these data suggest that endothelial cells express binding sites for TF.
View larger version (52K):
[in this window]
[in a new window]
| Fig 8.
Binding of endothelium to surfaces coated with
fragments of soluble TF. Fragments representing different regions of TF
were immobilized in microtiter wells. Endothelial cells were added in
the presence or absence of anti-TF MoAb (VIC7, IVC6, IID8) or control
MoAb (IgG). Cultures were incubated for 2 hours, washed, and the number
of adherent cells was quantitated. The extent of binding to fragments
was compared with the extent of binding to noncoated wells or wells
coated with BSA (A). Photomicrographs of endothelial cells incubated
for 2 hours in wells coated with a TF fragment representing amino acids
97-219 (B) or a fragment representing amino acids 1-122 (C).
Photographs were taken before cultures were washed to remove
nonadherent cells. These illustrate that TF fragment 97-219 supports
spreading of EC, but fragment 1-122 does not. Original magnification × 150. Results are the mean of at least three independent experiments
that were conducted using six replicates per parameter tested. HUVEC
binding to fragments 1-219 and 97-219 was increased to a statistically
signifcant degree over binding to control surfaces, P < .05. The block in binding to the full-length fragment by MoAb VIC7 and IID8
was also significantly lower than binding without addition of MoAb or
in the presence of control IgG, P < .05.
|
|
The fragments that promoted adhesion of HUVEC parallel those that block
reverse transmigration (compare Fig 8A to Fig 4). All anti-TF
MoAbs added to these incubations (VIC7, IVC6, and IID8), recognizing
different epitopes of TF, inhibited HUVEC binding to immobilized,
full-length TF (Fig 8A). However, because IVC6 and IID8 recognize
regions of TF that do not include amino acids 202-219,26 in
contrast to VIC7, their inhibitory effect in this assay must occur by
steric hindrance.
| |
DISCUSSION |
Using an in vitro model, we have identified a role for TF in
basal-to-apical transendothelial migration of MP. Monoclonal antibody
VIC7 against TF and soluble recombinant TF each strongly inhibited this
process, termed reverse transmigration, for at least 48 hours.
Identification of TF as a long-term mediator of reverse transmigration
in vitro will permit future exploration in vivo to determine whether
the molecular mechanism of basal-to-apical transendothelial migration
in vitro is predictive of the molecular events that mediate reverse
transmigration processes in vivo. Although the endothelial cells used
in this model are of vascular origin, this reverse transmigration model
appears to mimic at least some important aspects of lymphatic
clearance. Namely, a recent study has shown that p-glycoprotein,
another molecular mediator of reverse transmigration in this model,
also mediates lymphatic trafficking of human epidermal dendritic cells
and T lymphocytes.29 Moreover, reverse-transmigrated MP
collected from our cultures express phenotypic characteristics that are similar to cells recovered from lymph.31 That venular
endothelial cells appear to mimic at least some aspects of lymphatic
vessels in our cultures may be related to the known loss of specialized function in cultured endothelial cells32 and to the lack,
in our model, of other typical cellular features of a blood vessel wall, including pericytes and smooth muscle cells. As in our cultures, lymphatic vessels in vivo are not surrounded by interstitial
cells,33 as are blood vessels. Experiments are currently
under way to determine whether TF mediates reverse transmigration
across lymphatic endothelium and whether it mediates
ablumenal-to-lumenal migration of macrophage-derived foam cells across
arterial endothelium in atherosclerosis.
The expression of TF in atherosclerotic lesions is consistent with a
potential role in reverse transmigration from these lesions. As
observed using immuno-electron microscopy on atherosclerotic lesions in
pigeons, TF is expressed on macrophage-derived foam cells projecting
between endothelial cells and into the arterial lumen as they are
apparently migrating from the subendothelium.14 However, it
is not expressed by normocholesterolemic MP. Interestingly, the authors
of this study note that ablumenal-to-lumenal transendothelial migration
of foam cells appears to be associated with regression of
atherosclerotic lesions and that this regression is, in turn, associated with a transient increase in PCA on the
lesions.14
In general agreement with the present study, others have previously
reported induction of TF on monocytes cocultured with endothelium.34-36 Our experiments suggest that interactions
of MP with collagen is sufficient to induce TF expression. We observed a sustained, albeit relatively low, expression of TF for at least 24 hours. These kinetics are similar to those observed by Collins and
coworkers.35 However, others describe expression of TF that peaks at a high level at 4 hours but is greatly reduced by 24 hours.34,36 Perhaps interactions of MP with the collagenous matrix itself results in signals that modify the kinetics of TF expression. Sustained expression of TF also appears to occur in vivo,
as it is observed on resting peritoneal murine
macrophages37 and is a marker for differentiation of
monocytes to alveolar macrophages in rabbits.38
Because not all anti-TF MoAbs that inhibit coagulation block reverse
transmigration, the role of TF in reverse transmigration may be
independent of its procoagulative functions. However, we were not able
to inhibit PCA fully with anti-VII(a) MoAbs, leaving open the
possibility that VII(a) may play a role in this migration. Although the
exact mechanism by which TF mediates reverse transmigration is not
known, our experiments imply that TF on MP is involved in an adhesive
interaction. First, we found no evidence that TF acted as a
chemoattractant for MP, nor did anti-TF MoAb inhibit their migration
through collagen. Second, the finding that both anti-TF MoAb and
soluble TF inhibit reverse transmigration is consistent with a model in
which the binding of endogenous TF on MP to a putative endothelial
ligand is prevented by anti-TF MoAb and is competed with by soluble
recombinant TF. Third, we observed that, under conditions in which
monocytes express TF, anti-TF MoAb and soluble TF each inhibited
adhesion to the apical surface of the endothelial cells to a modest but
significant extent. Finally, we found that HUVEC would bind to soluble
TF fragments containing at least amino acid residues 202-208. Fragments
lacking these amino acids did not support adhesion. Best adhesion was observed using fragments that extended to residue 219. These data indicate that binding sites for TF are present on endothelium.
Fragments of TF that blocked reverse transmigration closely paralleled
those that supported endothelial cell adhesion. However, whereas only
MoAb VIC7 inhibited reverse transmigration strongly, all MoAbs tested
inhibited adhesion of HUVEC to soluble TF. Based on their epitope
specificities, only MoAb VIC7 could be binding directly to the critical
epitope to block adhesion of HUVEC to soluble TF. The other MoAbs
clearly blocked adhesion of HUVEC to TF by steric hindrance. Because
reverse transmigration assays are lengthy (48 hours), in contrast to
endothelial cell binding assays (2 hours), only a MoAb that binds
directly to the functional epitope with high affinity might be expected
to show inhibitory activity. Such a rationale might explain why MoAb
VIC7, but not other MoAbs, effectively inhibits reverse transmigration.
The effect of anti-TF MoAb on adhesion of LPS-stimulated monocytes to
the apical surface of endothelium is more modest than the inhibitory
effect of the MoAb on reverse transmigration. Possibly, an endothelial
cell ligand for TF is more abundantly expressed on the ablumenal
surface. Alternatively, there may be a difference in the number of
adhesive interactions available in the two circumstances. Reverse
transmigration may be mediated by very few adhesion molecules, whereas
monocytes can use multiple adhesive mechanisms to bind to the apical
surface of endothelium, so that antagonizing any single pathway does
not lead to inhibition of a large magnitude.39 Under
conditions in which circulating monocytes would be activated to express
TF, including exposure to LPS, many of these adhesive cascades that
mediate binding of monocytes to endothelium are activated, and the
effect of inhibiting only one involving TF would not likely be
extensive. Nevertheless, the finding that expression of TF promotes the
adhesion of cells to the apical (lumenal) surface of endothelium
suggests that this phenomenon may have pathophysiologic consequences in
addition to its role in reverse transendothelial migration.
In models of metastasis, tissue factor has a dual role. One of these
roles clearly requires its procoagulant activity,8 but the
other is dependent on residues in the cytoplasmic
tail8,9,40 and may be independent of prothrombinase
activity. Ligation of TF results in binding of its cytoplasmic tail to
actin binding protein 280. This interaction, in turn, facilitates
adhesion and spreading of TF+ cells, possibly via
interaction of a TF-VII(a) complex with cell surface- or matrix-bound
tissue factor pathway inhibitor (TFPI) or TFPI-2.40 On the
other hand, functional VII(a) may not be required for actin binding
protein recruitment, because a similar result can be obtained with
surrogate ligands.40 Plasminogen is a newly described
ligand for TF, which binds to cellular TF or TF
apoprotein.41 This binding interaction occurs at a site distinct from the VII(a) binding region of TF and results in activation of plasminogen to plasmin. Both TFPI42 and
plasminogen41 are presented on the endothelial cell surface
where they might serve as appropriate ligands for mediating reverse
transmigration. Thus, the possibility that these molecules or an
as-yet-undescribed ligand for TF mediates reverse transmigration awaits
future exploration.
| |
ACKNOWLEDGMENT |
We thank Drs Yale Nemerson and Arabinda Guha for generously providing
recombinant tissue factor and Drs Samuel Wright, John Harlan, and James
Young for gifts of MoAbs. We are indebted to the staff at Mt Sinai
Medical Center and the New York Blood Center for supplying umbilical
cords, and thank Ronald Liebman, Tricia Greene, and Elizabeth Polizzi
for assistance with endothelial cell culture. We extend additional
thanks to Dr Nemerson for critical reading of the manuscript.
| |
FOOTNOTES |
Submitted April 17, 1998;
accepted July 22, 1998.
Supported by NRSA grant HL09722 to G.J.R, and grant HL46849 to W.A.M.,
who is an Established Investigator of the American Heart Association.
The publication costs of this
article were defrayed in part by
page charge payment. This article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. section
1734 solely to indicate this fact.
Address reprint requests to Gwendalyn J. Randolph, PhD, 1300 York Ave,
Department of Pathology, Cornell University Medical College, New York,
NY 10021; e-mail: GJRandol{at}mail.med.cornell.edu.
| |
REFERENCES |
1.
Edgington TS, Mackman N, Brand K, Ruf W:
The structural biology of expression and function of tissue factor.
Thromb Haemost
66:67, 1991[Medline]
[Order article via Infotrieve]
2.
Luther T, Flössel C, Mackman N, Bierhaus A, Kasper M, Albrecht S, Sage EH, Iruela-Arispe L, Grossmann H, Ströhlein A, Zhang Y, Nawroth PP, Carmeliet P, Loskutoff DJ, Müller M:
Tissue factor expression during human and mouse development.
Am J Pathol
149:101, 1996[Abstract]
3.
Rosen ED, Chan JC, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Moons L, Collen D, Castellino FJ, Carmeliet P:
Mice lacking factor VII develop normally but suffer fatal perinatal bleeding.
Nature
390:290, 1997[Medline]
[Order article via Infotrieve]
4.
Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmbäck K, Danton MJS, Colbert MC, Witte DP, Fujikawa K, Davie EW, Degen JL:
Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation.
Proc Natl Acad Sci USA
93:6258, 1996[Abstract/Free Full Text]
5.
Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaederen I, Demunck H, Kasper M, Breier G, Evrard P, Müller M, Risau W, Edgington T, Collen D:
Role of tissue factor in embryonic blood vessel development.
Nature
383:73, 1996[Medline]
[Order article via Infotrieve]
6.
Toomey JR, Kratzer KE, Lasky NM, Broze GJ:
Effect of tissue factor deficiency on mouse and tumor development.
Proc Natl Acad Sci USA
94:6922, 1997[Abstract/Free Full Text]
7.
Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP:
Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice.
J Clin Invest
94:1320, 1994
8.
Müeller BM, Ruf W:
Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.
J Clin Invest
101:1372, 1998[Medline]
[Order article via Infotrieve]
9.
Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A:
Tissue factor promotes melanoma metastasis by a pathway independent of coagulation.
Proc Natl Acad Sci USA
92:8205, 1995[Abstract/Free Full Text]
10.
Osterud B, Flaegstad T:
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection related to an unfavorable prognosis.
Thromb Haemost
49:5, 1983[Medline]
[Order article via Infotrieve]
11.
Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Büller HR, van Deventer SJH, Hack CE, ten Cate J, Rosenger RD:
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees.
J Clin Invest
93:114, 1994
12.
Taylor FB, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS:
Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody.
Circ Shock
33:127, 1991[Medline]
[Order article via Infotrieve]
13.
Wilcox JN, Smith KM, Schwartz SM, Gordon D:
Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.
Proc Natl Acad Sci USA
86:2839, 1989[Abstract/Free Full Text]
14.
Landers SC, Gupta M, Lewis JC:
Ultrastructural localization of tissue factor on monocyte-derived macrophages and macrophage foam cells associated with atherosclerotic lesions.
Virchows Archiv
425:49, 1994[Medline]
[Order article via Infotrieve]
15.
Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT:
In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X.
Lab Invest
75:451, 1996[Medline]
[Order article via Infotrieve]
16.
Bellingan GJ, Caldwell HS, Howie EM, Dransfield I, Haslett C:
In vivo fate of the inflammatory macrophage during the resolution of inflammation.
J Immunol
157:2577, 1996[Abstract]
17.
Rosen H, Gordon S:
Adoptive transfer of fluorescence-labeled cells shows that resident peritoneal macrophages are able to migrate into specialized lymphoid organs and inflammatory sites in the mouse.
Eur J Immunol
20:1251, 1990[Medline]
[Order article via Infotrieve]
18.
Gerrity RG:
The role of the monocyte in atherogenesis. II. Migration of foam cells from atherosclerotic lesions.
Am J Pathol
103:191, 1981[Abstract]
19.
Faggiotto A, Ross R, Harker L:
Studies of hypercholesterolemia in the nonhuman primate.
Arteriosclerosis
4:323, 1984[Abstract/Free Full Text]
20.
Kling D, Holzchuh T, Betz E:
Recruitment and dynamics of leukocytes in the formation of arterial intimal thickening A comparative study with normo- and hypercholesterolemic rabbits.
Atherosclerosis
101:79, 1993[Medline]
[Order article via Infotrieve]
21.
Randolph GJ, Furie MB:
Mononuclear phagocytes egress from an in vitro model of the vascular wall by migrating across endothelium in the basal to apical direction: Role of intercellular adhesion molecule 1 and the CD11/CD18 integrins.
J Exp Med
183:451, 1996[Abstract/Free Full Text]
22.
Albrecht S, Luther T, Gromann H, Flössel C, Kotzsch M, Müller M:
An ELISA for tissue factor using monoclonal antibodies.
Blood Coagul Fibrinol
3:263, 1992[Medline]
[Order article via Infotrieve]
23.
Albrecht S, Kotzsch M, Siegert G, Luther T, Gromann H, Groer M, Müller M:
Detection of circulating tissue factor and factor VII in a normal population.
Thromb Haemost
75:772, 1996[Medline]
[Order article via Infotrieve]
24.
Muller WA, Ratti CM, McDonnell SL, Cohn ZA:
A human endothelial cell-restricted externally disposed plasmalemmal protein enriched in intercellular junctions.
J Exp Med
170:399, 1989[Abstract/Free Full Text]
25.
Muller WA, Weigl SA, Deng X, Phillips DM:
PECAM-1 is required for transendothelial migration of leukocytes.
J Exp Med
178:449, 1993[Abstract/Free Full Text]
26.
Magdolen V, Albrecht S, Kotzsch M, Haller C, Bürgle M, Jacob U, Groer M, Kessler H, Graeff H, Müller M, Schmitt M, Luther T:
Immunological and functional analyses of the extracellular domain of human tissue factor.
Biol Chem (Germany)
379:157, 1998
27.
Muller WA, Weigl SA:
Monocyte-selective transendothelial migration: Dissection of the binding and transmigration phases by an in vitro assay.
J Exp Med
176:819, 1992[Abstract/Free Full Text]
28.
Wilkinson PC:
Chemotaxis and Inflammation. Edinburgh, UK, Churchill Livingston, 1982.
29.
Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman RM, Muller WA:
A physiologic function for p-glycoprotein (MDR-1) during mobilization of dendritic cells from skin via afferent lymphatic vessels.
Proc Natl Acad Sci USA
95:6924, 1998[Abstract/Free Full Text]
30.
Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A:
Tissue factor induces migration of cultured aortic smooth muscle cells.
Thromb Haemost
75:389, 1996[Medline]
[Order article via Infotrieve]
31. Randolph GJ, Beaulieu S, Lebecque S, Steinman RM, Muller WA:
Differentiation of monocytes into dendritic cells in a model of
transendothelial trafficking. Science (in press)
32.
Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt A-M, Stern DM:
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
Blood
91:3527, 1998[Free Full Text]
33.
Fraley EE, Weiss L:
An electron microscopy study of the lymphatic vessels in the penile skin of the rat.
Am J Anat
109:85, 1961
34.
Lewis JC, Jones NL, Hermanns MI, Röhrig O, Klein CL, Kirkpatrick CJ:
Tissue factor expression during coculture of endothelial cells and monocytes.
Exp Mol Pathol
62:207, 1995[Medline]
[Order article via Infotrieve]
35.
Collins PW, Noble KE, Reittie JR, Hoffbrand AV, Pasi KJ, Yong KL:
Induction of tissue factor expression in human monocyte/endothelium cocultures.
Br J Haemotol
91:963, 1995[Medline]
[Order article via Infotrieve]
36.
Lo SK, Cheung A, Zheng Q, Silverstein RL:
Induction of tissue factor on monocytes by adhesion to endothelial cells.
J Immunol
154:4768, 1995[Abstract]
37.
Lyberg T, Amlie E, Kaplun A, Prydz H:
Macrophage heterogeneity in thromboplastin response.
Scand J Immunol
18:235, 1983[Medline]
[Order article via Infotrieve]
38.
Rothberger H, McGee MP, Lee TK:
Tissue factor activity. A marker of alveolar macrophage maturation in rabbits. Effects of granulomatous pneumonitis.
J Clin Invest
73:1524, 1984
39.
Meerschaert J, Furie MB:
The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium.
J Immunol
154:4099, 1995[Abstract]
40.
Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W:
A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280.
J Cell Biol
140:1241, 1998[Abstract/Free Full Text]
41.
Fan Z, Larson PL, Bognacki J, Raghunath PN, Tomaszewski JE, Kuo A, Canziani G, Chaiken I, Cines DB, Higazi AA:
Tissue factor regulates plasminogen binding and activation.
Blood
91:1987, 1998[Abstract/Free Full Text]
42.
Broze GJ:
Tissue factor pathway inhibitor and the revised theory of coagulation.
Annu Rev Med
46:103, 1995[Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. L. V. Westhorpe, J. Zhou, N. L. Webster, B. Kalionis, S. R. Lewin, A. Jaworowski, W. A. Muller, and S. M. Crowe
Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages
J. Leukoc. Biol.,
June 1, 2009;
85(6):
1027 - 1035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shinagawa, V. A. Ploplis, and F. J. Castellino
A severe deficiency of coagulation factor VIIa results in attenuation of the asthmatic response in mice
Am J Physiol Lung Cell Mol Physiol,
May 1, 2009;
296(5):
L763 - L770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Girardi and N Mackman
Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule
Lupus,
October 1, 2008;
17(10):
931 - 936.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Moosbauer, E. Morgenstern, S. L. Cuvelier, D. Manukyan, K. Bidzhekov, S. Albrecht, P. Lohse, K. D. Patel, and B. Engelmann
Eosinophils are a major intravascular location for tissue factor storage and exposure
Blood,
February 1, 2007;
109(3):
995 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Tilley, B. Pedersen, R. Pawlinski, Y. Sato, J. H. Erlich, Y. Shen, S. Day, Y. Huang, D. T. Eitzman, W. A. Boisvert, et al.
Atherosclerosis in Mice Is Not Affected by a Reduction in Tissue Factor Expression
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2006;
26(3):
555 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, M. Kasper, T. Heck, K. Nakagawa, P. M. Humpert, L. Bai, G. Wu, Y. Zhang, T. Luther, M. Andrassy, et al.
Tissue Factor as a Link Between Wounding and Tissue Repair
Diabetes,
July 1, 2005;
54(7):
2143 - 2154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. M. Rao and U. R. Pendurthi
Tissue Factor-Factor VIIa Signaling
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2005;
25(1):
47 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Qu, E. W. Edwards, F. Tacke, V. Angeli, J. Llodra, G. Sanchez-Schmitz, A. Garin, N. S. Haque, W. Peters, N. van Rooijen, et al.
Role of CCR8 and Other Chemokine Pathways in the Migration of Monocyte-derived Dendritic Cells to Lymph Nodes
J. Exp. Med.,
November 15, 2004;
200(10):
1231 - 1241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dorfleutner, E. Hintermann, T. Tarui, Y. Takada, and W. Ruf
Cross-talk of Integrin {alpha}3{beta}1 and Tissue Factor in Cell Migration
Mol. Biol. Cell,
October 1, 2004;
15(10):
4416 - 4425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Sharma, E. Melis, M. J. Hickey, C. D. Clyne, J. Erlich, L. M. Khachigian, P. Davenport, E. Morand, P. Carmeliet, and P. G. Tipping
The Cytoplasmic Domain of Tissue Factor Contributes to Leukocyte Recruitment and Death in Endotoxemia
Am. J. Pathol.,
July 1, 2004;
165(1):
331 - 340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ahamed and W. Ruf
Protease-activated Receptor 2-dependent Phosphorylation of the Tissue Factor Cytoplasmic Domain
J. Biol. Chem.,
May 28, 2004;
279(22):
23038 - 23044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Moldenhauer, M. Nociari, G. Lam, A. Salama, S. Rafii, and M. A.S. Moore
Tumor Necrosis Factor Alpha-Stimulated Endothelium: An Inducer of Dendritic Cell Development from Hematopoietic Progenitors and Myeloid Leukemic Cells
Stem Cells,
March 1, 2004;
22(2):
144 - 157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Yang, P. Hall, G. Milenkovski, L. Sharma, P. Hutchinson, E. Melis, P. Carmeliet, P. Tipping, and E. Morand
Reduction in Arthritis Severity and Modulation of Immune Function in Tissue Factor Cytoplasmic Domain Mutant Mice
Am. J. Pathol.,
January 1, 2004;
164(1):
109 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Crowe, T. Zhu, and W. A. Muller
The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection
J. Leukoc. Biol.,
November 1, 2003;
74(5):
635 - 641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Chong, T. H. Pohlman, C. R. Hampton, A. Shimamoto, N. Mackman, and E. D. Verrier
Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury
Ann. Thorac. Surg.,
February 1, 2003;
75(2):
S649 - 655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Qu, T. M. Moran, and G. J. Randolph
Autocrine Type I IFN and Contact with Endothelium Promote the Presentation of Influenza A Virus by Monocyte-Derived APC
J. Immunol.,
January 15, 2003;
170(2):
1010 - 1018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Versteeg, B. B. Sorensen, S. H. Slofstra, J. H. M. Van den Brande, J. C. Stam, P. M. P. van Bergen en Henegouwen, D. J. Richel, L. C. Petersen, and M. P. Peppelenbosch
VIIa/Tissue Factor Interaction Results in a Tissue Factor Cytoplasmic Domain-independent Activation of Protein Synthesis, p70, and p90 S6 Kinase Phosphorylation
J. Biol. Chem.,
July 19, 2002;
277(30):
27065 - 27072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Neve, D. Corseaux, G. Chinetti, C. Zawadzki, J.-C. Fruchart, P. Duriez, B. Staels, and B. Jude
PPAR{{alpha}} Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages
Circulation,
January 16, 2001;
103(2):
207 - 212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. W. Verheul, A. S. Jorna, K. Hoekman, H. J. Broxterman, M. F. B. G. Gebbink, and H. M. Pinedo
Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets
Blood,
December 15, 2000;
96(13):
4216 - 4221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Erlich, E. M. Boyle, J. Labriola, J. C. Kovacich, R. A. Santucci, C. Fearns, E. N. Morgan, W. Yun, T. Luther, O. Kojikawa, et al.
Inhibition of the Tissue Factor-Thrombin Pathway Limits Infarct Size after Myocardial Ischemia-Reperfusion Injury by Reducing Inflammation
Am. J. Pathol.,
December 1, 2000;
157(6):
1849 - 1862.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Muller, E. M. A. Mervaala, F. Schmidt, J.-K. Park, R. Dechend, E. Genersch, V. Breu, B.-M. Loffler, D. Ganten, W. Schneider, et al.
Effect of Bosentan on NF-{kappa}B, Inflammation, and Tissue Factor in Angiotensin II-Induced End-Organ Damage
Hypertension,
August 1, 2000;
36(2):
282 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Muller, E. M. A. Mervaala, R. Dechend, A. Fiebeler, J.-K. Park, F. Schmidt, J. Theuer, V. Breu, N. Mackman, T. Luther, et al.
Angiotensin II (AT1) Receptor Blockade Reduces Vascular Tissue Factor in Angiotensin II-Induced Cardiac Vasculopathy
Am. J. Pathol.,
July 1, 2000;
157(1):
111 - 122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Rauch, D. Bonderman, B. Bohrmann, J. J. Badimon, J. Himber, M. A. Riederer, and Y. Nemerson
Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor
Blood,
July 1, 2000;
96(1):
170 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dechend, V. Homuth, G. Wallukat, J. Kreuzer, J. K. Park, J. Theuer, A. Juepner, D. C. Gulba, N. Mackman, H. Haller, et al.
AT1 Receptor Agonistic Antibodies From Preeclamptic Patients Cause Vascular Cells to Express Tissue Factor
Circulation,
May 23, 2000;
101(20):
2382 - 2387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Esmon
Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
Blood,
February 15, 2000;
95(4):
1113 - 1116.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Akuzawa, M. Kurabayashi, Y. Ohyama, M. Arai, and R. Nagai
Zinc Finger Transcription Factor Egr-1 Activates Flt-1 Gene Expression in THP-1 Cells on Induction for Macrophage Differentiation
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2000;
20(2):
377 - 384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Camerer, J.-A. Rottingen, E. Gjernes, K. Larsen, A. H. Skartlien, J.-G. Iversen, and H. Prydz
Coagulation Factors VIIa and Xa Induce Cell Signaling Leading to Up-regulation of the egr-1 Gene
J. Biol. Chem.,
November 5, 1999;
274(45):
32225 - 32233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Versteeg, I. Hoedemaeker, S. H. Diks, J. C. Stam, M. Spaargaren, P. M. P. van Bergen en Henegouwen, S. J. H. van Deventer, and M. P. Peppelenbosch
Factor VIIa/Tissue Factor-induced Signaling via Activation of Src-like Kinases, Phosphatidylinositol 3-Kinase, and Rac
J. Biol. Chem.,
September 8, 2000;
275(37):
28750 - 28756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Top
Abstract
Introduction